Articles

Lifestyle changes and risk of cancer: experience from the Swedish women's lifestyle and health cohort study

Edoardo Botteri, Paula Berstad, Sven Sandin, Elisabete Weiderpass. Acta Oncol. 2021 Jul;60(7):827-834

We investigated this issue in the Swedish Women's Lifestyle and Health Cohort Study. We included 29,930 women. From 1991/92 to 2003, median age changed from 40.0 to 51.7 years, alcohol consumption from 2.5 to 4.7 grams/day, BMI from 22.7 to 24.5 kg/m2, proportion of current smokers from 31.0 to 20.6% and women repo... Read More

13 May, 2026

Healthy Lifestyle and Cancer Risk: Modifiable Risk Factors to Prevent Cancer

Pasquale Marino, Mariangela Mininni, Giovanni Deiana, et al. Nutrients. 2024 Mar 11;16(6):800

Cancer has become a serious problem worldwide, as it represents the main cause of death, and its incidence has increased over the years. A potential strategy to counter the growing spread of various forms of cancer is the adoption of prevention strategies, particularly the use of healthy lifestyles, such as maintai... Read More

13 May, 2026

De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial

Xiu-Chun Chen, De-Chuang Jiao, Jiang-Hua Qiao, et al. Lancet Oncol. 2025 Jan;26(1):27-36

We aimed to evaluate the efficacy of weekly nab-paclitaxel compared with the standard regimen of docetaxel plus carboplatin, both with trastuzumab and pertuzumab, as neoadjuvant therapies for patients with HER2-positive breast cancer. Between Sept 20, 2020, and March 1, 2023, 689 eligible patients were randomly as... Read More

13 May, 2026

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

Peter Schmid, Javier Cortes, Rebecca Dent, et al. N Engl J Med. 2024 Nov 28;391(21):1981-1991

In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the addition of pembrolizumab to platinum-containing chemotherapy. Here we report the final results for overall survival. chemothe... Read More

13 May, 2026

Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial

Fatima Cardoso, Joyce O'Shaughnessy, Zhenzhen Liu, et al. Nat Med. 2025 Feb;31(2):442-448

We conducted a double-blind, placebo-controlled phase 3 study (KEYNOTE-756) in which patients with previously untreated ER+/HER2-grade 3 high-risk invasive breast cancer (T1c-2 (≥2 cm), cN1-2 or T3-4, cN0-2) were randomly assigned (1:1) to neoadjuvant pembrolizumab 200 mg or placebo Q3W given with paclitaxel QW for... Read More

13 May, 2026

Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial

Sherene Loi, Roberto Salgado, Giuseppe Curigliano, et al. Nat Med. 2025 Feb;31(2):433-441

We conducted a randomized, multicenter, double-blind phase 3 trial to investigate the benefit of adding nivolumab to neoadjuvant chemotherapy in patients with newly diagnosed, high-risk, grade 3 or 2 (ER 1 to ≤10%) ER+/HER2- primary BC. In total, 510 patients were randomized to receive anthracycline and taxane-base... Read More

13 May, 2026

Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial

Elizabeth A Mittendorf, Zoe June Assaf, Nadia Harbeck, et al. Nat Med. 2025 Jul;31(7):2397-2404

Patients with previously untreated stage II/III TNBC enrolled in 75 academic and community sites in 13 countries were randomized 1:1 to receive neoadjuvant chemotherapy with either peri-operative atezolizumab (n = 165) or preoperative placebo (n = 168). Descriptive secondary endpoints included event-free, disease-f... Read More

13 May, 2026

Prediction of survival after de-escalated neoadjuvant therapy in HER2-positive early breast cancer: a pooled analysis of three WSG trials

M Graeser, O Gluz, C Zu Eulenburg, et al. Ann Oncol. 2025 Nov;36(11):1366-1378

A total of 713 patients were analyzed; neoadjuvant chemotherapy (paclitaxel plus pertuzumab plus trastuzumab): n = 149, neoadjuvant chemotherapy-free (pertuzumab plus trastuzumab, trastuzumab-only)/antibody-drug conjugate (ADC, trastuzumab emtansine) treatment: n = 564. Patients with pathological complete response... Read More

13 May, 2026

AGO Breast Commission recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2025

Toralf Reimer, Thorsten Kuehn, Volkmar Mueller, et al. Eur J Surg Oncol 2025 Nov;51(11):110445

The German Guideline Commission (AGO: Working Group on Gynecologic Cancers) updated its recommendations on the diagnosis and treatment of breast cancer in March 2025. The most important changes include the incorporation of INSEMA and SOUND trial results into the guidelines. In patients with low-risk characteristics... Read More

13 May, 2026

Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial

N Harbeck, S Modi, L Pusztai, et al. Ann Oncol. 2026 Feb;37(2):166-179

DESTINY-Breast11 assessed efficacy and safety of neoadjuvant trastuzumab deruxtecan (T-DXd) alone or followed by paclitaxel + trastuzumab + pertuzumab (THP) versus dose-dense doxorubicin + cyclophosphamide (ddAC) followed by THP for high-risk (≥cT3cN0 or cT0-4cN1-3) HER2-positive disease. 286 (T-DXd), 321 (T-DXd-TH... Read More

12 May, 2026